Results 81 to 90 of about 13,766 (257)
Current Opinion in Infectious Diseases, 2014 Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications.Echinocandin resistance has emerged over the ...
Maiken Cavling Arendrup, David S. Perlin
openaire +3 more sources
Emerging Threats in Antifungal-Resistant Fungal Pathogens. [PDF]
, 2016 The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species.
Sanglard, D.
core +2 more sources
Echinocandins for candidemia: a rational choice
Reviews in Health Care, 2013 Among antifungal drugs, echinocandins (micafungin, caspofungin and anidulafungin) represent a rational choice for the first-line therapy of candidemia/invasive candidiasis in critically ill patients. Among other properties characterizing echinocandins, it’s important to emphasize the broad spectrum of activity, the fungicidal activity against the ...
Menichetti, Francesco +1 more
openaire +4 more sources
Polymer Engineering &Science, Volume 65, Issue 6, Page 3178-3192, June 2025.Schematic illustration of prepared poly(DEAEMA‐co‐EMA)/PIN composities and 3D AFM image. Abstract In the current study, in the first stage, amphiphilic poly(2‐diethylamino ethylmethacrylate‐co‐ethyl methacrylate) [Poly(DEAEMA‐co‐EMA)] was synthesized from the 2‐diethylamino ethylmethacrylate (DEAEMA) and the ethyl methacrylate (EMA) using the free ...
Safiye Elif Korcan +4 more
wiley +1 more source
Reviews Of Anti‐infective Agents: Anidulafungin: A Novel Echinocandin [PDF]
Clinical Infectious Diseases, 2006 Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significant limitations. Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections.
Jose A. Vazquez, Jack D. Sobel
openaire +3 more sources
Clinical Transplantation, Volume 39, Issue 6, June 2025.ABSTRACT Background There are no established recommendations for systematic or targeted antifungal prophylaxis in heart transplant recipients (HTRs), resulting in heterogeneous practices. An outbreak of post‐surgical invasive aspergillosis (IA) among HTR, which coincided with construction activities near our heart transplant unit, prompted the ...
Malo Penven +9 more
wiley +1 more source
Cell Reports, 2018 Summary: Candida albicans is a leading cause of death due to fungal infection. Treatment of systemic candidiasis often relies on echinocandins, which disrupt cell wall synthesis. Resistance is readily acquired via mutations in the drug target gene, FKS1.
Tavia Caplan +6 more
doaj
Candida auris, what do paediatricians need to know? [PDF]
, 2018 AW is supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of Aberdeen.Peer reviewedPublisher ...
Warris, Adilia
core +1 more source
Mycoses, Volume 68, Issue 6, June 2025.ABSTRACT Candida infections represent a major component of invasive and non‐invasive mycoses globally, including the countries in the Arabian Peninsula. In this review, we present epidemiological features and trends, clinical manifestations, species distribution, antifungal susceptibility, and outcomes available for candidemia and candiduria in six ...
Suhail Ahmad +14 more
wiley +1 more source
Biotechnology Reports, 2018 Echinocandin B is a potent antifungal against the majority of fungal pathogens and its biosynthesis occurred by ecd and hty gene clusters in Emericella rugulosa NRRL 11440. We elucidated the functional necessity of in-clustered transcription factor; ecdB
Arvind Kumar +4 more
doaj